HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

To report the 96-week outcomes from HAWK and HARRIER. Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of brolucizumab 3 mg (HAWK only) and 6 mg with aflibercept 2 mg in eyes with neovascular age-related macular degeneration (nAMD). Treatment-naïve e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Jg. 128; H. 1; S. 89
Hauptverfasser:	Dugel, Pravin U, Singh, Rishi P, Koh, Adrian, Ogura, Yuichiro, Weissgerber, Georges, Gedif, Kinfemichael, Jaffe, Glenn J, Tadayoni, Ramin, Schmidt-Erfurth, Ursula, Holz, Frank G
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.01.2021
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Follow-Up Studies Humans Macula Lutea - pathology Prospective Studies Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Recombinant Fusion Proteins - administration & dosage Time Factors Tomography, Optical Coherence - methods Treatment Outcome Visual Acuity - drug effects Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
ISSN:	1549-4713, 1549-4713
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!